Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 8/20 | 0.56 |
| ▸ | PI4K2B | Q8TCG2 | 8/20 | 0.56 |
| ▸ | PI4K2A | Q9BTU6 | 8/20 | 0.56 |
| ▸ | PI4KB | Q9UBF8 | 8/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.51 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6684462 | 0.81 | PI4KA (0.60) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL5433391 | 0.81 | PI4KA (0.36) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL6533716 | 0.81 | EGLN1 (0.39) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL669406 | 0.79 | ADORA2A (0.40) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL18757974 | 0.78 | PI4KA (0.69) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL7063134 | 0.77 | PDPK1 (0.37) | — | |
| SCHEMBL27260776 | 0.75 | PI4KA (0.66) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL4424909 | 0.75 | ADORA2A (0.56) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL20399056 | 0.74 | PI4KA (0.56) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL17574490 | 0.74 | LMNA (0.59) | ADORA2AADORA1NUDT1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 784 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9284343-B2 | 2′-O-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-03-15 | — | — | US | claimed |
| WO-2013071079-A1 | LIN28/LET-7 CRYSTAL STRUCTURES, PURIFICATION PROTOCOLS, AND MOLECULAR PROBES SUITABLE FOR SCREENING ASSAYS AND THERAPEUTICS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-05-16 | — | — | WO | claimed |
| US-20040214198-A1 | Allele-targeted RNA interference | UNIVERSITY OF MASSACHUSETTS | 2004-10-28 | — | — | US | claimed |
| WO-2004046324-A2 | ALLELE-TARGETED RNA INTERFERENCE | UNIVERSITY OF MASSACHUSETTS (US) | 2004-06-03 | — | — | WO | claimed |
| WO-2024151685-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-18 | — | — | US | disclosed |
| US-20240238473-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-07-18 | — | — | US | disclosed |
| WO-2024151673-A2 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151687-A1 | GENETIC SWITCHES AND THEIR USE IN TREATING CANCER | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| EP-4392140-A1 | IN VITRO TRANSCRIPTION TECHNOLOGIES | BioNTech SE (DE) | 2024-07-03 | — | — | EP | disclosed |
| WO-2024133160-A1 | HEPATITIS B COMPOSITIONS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-06-27 | — | — | WO | disclosed |
| US-20240209068-A1 | MUCOSAL EXPRESSION OF ANTIBODY STRUCTURES AND ISOTYPES BY MRNA | MODERNATX, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-7585851-B2 | 3′-prodrugs of 2′-deoxy-β-L-nucleosides | IDENIX PHARMACEUTICALS, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| EP-1986699-A2 | RNA INTERFERENCE AGENTS FOR THERAPEUTIC USE | University of Massachusetts (US) | 2008-11-05 | — | — | EP | disclosed |
| EP-1986609-A2 | RNA SILENCING AGENTS FOR USE IN THERAPY AND NANOTRANSPORTERS FOR EFFICIENT DELIVERY OF SAME | University of Massachusetts (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20080125386-A1 | RNA interference agents for therapeutic use | UNIVERSTIY OF MASSACHUSETTS (US) | 2008-05-29 | — | — | US | disclosed |
| WO-2007092182-A2 | RNA INTERFERENCE AGENTS FOR THERAPEUTIC USE | UNIVERSITY OF MASSACHUSETTS (US) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007089607-A2 | RNA SILENCING AGENTS FOR USE IN THERAPY AND NANOTRANSPORTERS FOR EFFICIENT DELIVERY OF SAME | UNIVERSITY OF MASSACHUSETTS (US) | 2007-08-09 | — | — | WO | disclosed |
| US-20040214198-A1 | Allele-targeted RNA interference | UNIVERSITY OF MASSACHUSETTS | 2004-10-28 | — | — | US | disclosed |
| WO-2004046324-A2 | ALLELE-TARGETED RNA INTERFERENCE | UNIVERSITY OF MASSACHUSETTS (US) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209068-A1 | MUCOSAL EXPRESSION OF ANTIBODY STRUCTURES AND ISOTYPES BY MRNA | NSUN3, IGLV6-57, MRPS23 | PI4KA 1891/4885PI4K2B 3222/4885PI4K2A 2709/4885 |
| US-20080125386-A1 | RNA interference agents for therapeutic use | HNRNPH1, SNRPE, RNASEH1 | PI4KA 4184/4885PI4K2B 3836/4885PI4K2A 3547/4885 |
| US-20240238473-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | CHI3L2, CHI3L1, FGF2 | PI4KA 3158/4885PI4K2B 2415/4885PI4K2A 2491/4885 |
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC47A1, TMEM205 | PI4KA 1216/4885PI4K2B 1892/4885PI4K2A 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.